{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:47:15Z","timestamp":1786708035924,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Complementary Therapies in Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ctim.2023.102939","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T21:20:36Z","timestamp":1677705636000},"page":"102939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Integrative medicine in multiple myeloma and plasma cell disorders"],"prefix":"10.1016","volume":"73","author":[{"given":"Onyemaechi","family":"Okolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy C.","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan W.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Ahlstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisstina","family":"Gowin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctim.2023.102939_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.pop.2016.07.002","article-title":"Plasma cell disorders","volume":"43","author":"Castillo","year":"2016","journal-title":"Prim Care"},{"issue":"1","key":"10.1016\/j.ctim.2023.102939_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.ctim.2023.102939_bib3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctim.2023.102939_bib4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"29","key":"10.1016\/j.ctim.2023.102939_bib5","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctim.2023.102939_bib6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/pon.5039","article-title":"Health-related quality of life among US adults with cancer: potential roles of complementary and alternative medicine for health promotion and well-being","volume":"28","author":"Rhee","year":"2019","journal-title":"Psychooncology"},{"issue":"52","key":"10.1016\/j.ctim.2023.102939_bib7","article-title":"A comprehensive definition for integrative oncology","volume":"2017","author":"Witt","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"52","key":"10.1016\/j.ctim.2023.102939_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgx004","article-title":"Growth of integrative medicine at leading cancer centers between 2009 and 2016: a systematic analysis of NCI-designated comprehensive cancer center websites","volume":"2017","author":"Yun","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ctim.2023.102939_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctcp.2019.01.004","article-title":"Complementary and alternative medicine use in cancer: a systematic review","volume":"35","author":"Keene","year":"2019","journal-title":"Complement Ther Clin Pract"},{"issue":"9\u201310","key":"10.1016\/j.ctim.2023.102939_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1089\/acm.2018.0169","article-title":"An integrative approach to prostate cancer","volume":"24","author":"Abrams","year":"2018","journal-title":"J Alter Complement Med"},{"issue":"3","key":"10.1016\/j.ctim.2023.102939_bib11","first-page":"194","article-title":"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment","volume":"67","author":"Greenlee","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ctim.2023.102939_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.mcna.2017.04.011","article-title":"Integrative oncology","volume":"101","author":"Lopez","year":"2017","journal-title":"Med Clin N Am"},{"issue":"8","key":"10.1016\/j.ctim.2023.102939_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JOP.18.00283","article-title":"Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO CLinical Practice Guideline Summary","volume":"14","author":"Lyman","year":"2018","journal-title":"J Oncol Pract"},{"issue":"4","key":"10.1016\/j.ctim.2023.102939_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11899-019-00526-8","article-title":"Emerging role of integrative medicine in hematologic malignancies: a literature review and update on current trends in complementary medical practices in hematologic cancers","volume":"14","author":"Okolo","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1016\/j.ctim.2023.102939_bib15","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctim.2023.102939_bib16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ctim.2023.102939_bib17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.MLR.0000093487.78664.3C","article-title":"The Patient Health Questionnaire-2: validity of a two-item depression screener","volume":"41","author":"Kroenke","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.ctim.2023.102939_bib18","unstructured":"Center for Disease Control and Prevention. BRFSS Questionnaires. \u3008https:\/\/www.cdc.gov\/brfss\/about\/index.htm\u3009."},{"issue":"10\u201311","key":"10.1016\/j.ctim.2023.102939_bib19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1177\/1359105318772073","article-title":"Unmet needs and quality of life in multiple myeloma patients","volume":"25","author":"Pereira","year":"2020","journal-title":"J Health Psychol"},{"issue":"1","key":"10.1016\/j.ctim.2023.102939_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.seminoncol.2022.01.002","article-title":"Examining health related quality of life outcomes in multiple myeloma: past and future perspectives","volume":"49","author":"Hevroni","year":"2022","journal-title":"Semin Oncol"},{"issue":"21","key":"10.1016\/j.ctim.2023.102939_bib21","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1002\/cam4.3391","article-title":"Health-related quality of life of patients with multiple myeloma: a real-world study in China","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.ctim.2023.102939_bib22","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-related quality of life after autologous stem cell transplantation for multiple myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2\u20133","key":"10.1016\/j.ctim.2023.102939_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10376178.2019.1623699","article-title":"Factors influencing quality of life in patients with multiple myeloma","volume":"55","author":"Kang","year":"2019","journal-title":"Conte Nurse"},{"issue":"2","key":"10.1016\/j.ctim.2023.102939_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-020-00570-9","article-title":"Supportive care in multiple myeloma","volume":"15","author":"Guzdar","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.ctim.2023.102939_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CCO.0000000000000376","article-title":"Integrative medicine in cancer survivors","volume":"29","author":"Viscuse","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"10.1016\/j.ctim.2023.102939_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCO.0000000000000733","article-title":"Models of supportive care in oncology","volume":"33","author":"Hui","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1016\/j.ctim.2023.102939_bib27","first-page":"4055","article-title":"Correlation between an integrative oncology treatment program and survival in patients with advanced gynecological cancer","volume":"29","author":"Segev","year":"2021","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ctim.2023.102939_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0000000000000399","article-title":"Integrative medicine therapies for pain management in cancer patients","volume":"25","author":"Deng","year":"2019","journal-title":"Cancer J"},{"issue":"24","key":"10.1016\/j.ctim.2023.102939_bib29","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1002\/cam4.3566","article-title":"The SIMM study: survey of integrative medicine in myeloproliferative neoplasms","volume":"9","author":"Gowin","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctim.2023.102939_bib30","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3389\/fphar.2019.01614","article-title":"Phytochemicals in cancer treatment: from preclinical studies to clinical practice","volume":"10","author":"Choudhari","year":"2019","journal-title":"Front Pharm"},{"issue":"9","key":"10.1016\/j.ctim.2023.102939_bib31","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0043-109558","article-title":"Targeting multiple myeloma cancer stem cells with natural products \u2013 lessons from other hematological malignancies","volume":"83","author":"Issa","year":"2017","journal-title":"Planta Med"},{"issue":"12","key":"10.1016\/j.ctim.2023.102939_bib32","first-page":"14","article-title":"Multiple myeloma: possible cure from the sea","author":"Capalbo","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ctim.2023.102939_bib33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/1871520620666200918113625","article-title":"Anti-cancer activity of curcumin on multiple myeloma","volume":"21","author":"Mirzaei","year":"2021","journal-title":"Anticancer Agents Med Chem"}],"container-title":["Complementary Therapies in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229923000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229923000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:18:23Z","timestamp":1760807903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0965229923000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":33,"alternative-id":["S0965229923000262"],"URL":"https:\/\/doi.org\/10.1016\/j.ctim.2023.102939","relation":{},"ISSN":["0965-2299"],"issn-type":[{"value":"0965-2299","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative medicine in multiple myeloma and plasma cell disorders","name":"articletitle","label":"Article Title"},{"value":"Complementary Therapies in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctim.2023.102939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102939"}}